

## [370] CTG PHARMA- SAFE CAR T THERAPY FOR SOLID TUMORS

Yoav Ben Ya'acov, CEO, CTG Pharma, Rehovot, Israel

- **Investment Rational**

CTG develops a biological solution to enable the use of CAR T therapy for the treatment of solid tumors

- **Business Strategy**

- **Core Technology**

In order to avoid the 'On-target/Off-tumor toxicity', the company builds a rationally designed library of 65K 'ON switches', for inducible expression of any CAR for the treatment of any type of cancer. The chosen ON switch ensures that the engineered T cells will target only tumor cells expressing the target antigen.

- **Product Profile/Pipeline**

The Proof Of Concept was achieved on Her2+ breast cancer. Yet, the platform is unlimited and potentially applicable to other types of cancer and CAR T therapies.

- **What's Next?**

R&D

Preclinical / Clinicals

Organizational plans

Financial plans